Hideki Nakayama

8PUBLICATIONS
16CO-AUTHORS
Child and adolescent developmentHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)Medical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 13, 2026
Twenty-Year Follow-Up After Pediatric PBSCT and Living-Donor Lung Transplantation From the Original Donor: Late Benefit of Belumosudil for Chronic GVHD.

Kensuke Kawaguchi, Shunichiro Toya, Satomi Yokoyama

|May 08, 2024
Three-year update outcomes of the first chimeric antigen receptor-T therapy for children and young adults with relapsed/refractory acute lymphoblastic leukemia.

Hideki Nakayama

|Mar 21, 2023
Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).

Hideki Nakayama, Chitose Ogawa, Masahiro Sekimizu

|May 31, 2022
A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).

Hideki Nakayama, Chitose Ogawa, Masahiro Sekimizu

|Sep 02, 2021
Correction to: Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.

Takashi Taga, Shiro Tanaka, Daisuke Hasegawa

|Feb 16, 2021
Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.

Takashi Taga, Shiro Tanaka, Daisuke Hasegawa

Pageof 2

Frequent Collaborators

3 joint publications

Hiroshi Moritake

3 joint publications

Takako Miyamura

3 joint publications

Daisuke Hasegawa

3 joint publications

Shotaro Iwamoto